- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer Center
NCI CANCERLIT® Search: Hairy Cell Leukemia - January 2002
National Cancer Institute®
Last Modified: January 1, 2002
Table of Contents
1
UI - 11675521
AU - Hounshell J; Tomori C; Newlin R; Knox K; Rundhaugen L; Tallman M;
TI -
Bennett C
Changes in finances, insurance, employment, and lifestyle among persons
diagnosed with hairy cell leukemia.
SO - Oncologist 2001;6(5):435-40
AD - VA Chicago Health Care System-Lakeside Division, Chicago, Illinois
60611, USA.
BACKGROUND: While being cured of cancer generally leads to a life
expectancy similar to that of the general population, the extent to
which other aspects of life are affected is unknown. To address these
concerns, patients with hairy cell leukemia, a cancer with a very high
cure rate, were queried about employment, insurance, finances, and
lifestyle during and following their treatment. METHODS: Study
participants (n = 31) ranging in age from 24 to 73 years at the time of
diagnosis (median, 49 years) were surveyed regarding changes in health
and life insurance, employment, out-of-pocket medical costs, exercise,
diet, and use of mental and alternative health services that occurred
during or following hairy cell leukemia treatment. RESULTS: Following a
diagnosis of hairy cell leukemia, 61.3% of the respondents paid for some
aspect of medical care in spite of having health insurance coverage at
the time of diagnosis. Four respondents (12.9%) could not obtain health
insurance following treatment, and the occupational choices of several
individuals or their spouses were based in large part on a desire to
obtain or maintain comprehensive health insurance. Of the 13 individuals
who attempted to purchase life insurance, 10 had difficulty obtaining a
policy or were denied coverage. Lifestyle changes were noted by 40% to
60% of respondents, and included reports of more frequent exercise,
adoption of a healthier diet, and having a greater appreciation for
life, loved ones, and physical health. CONCLUSIONS: While hairy cell
leukemia is a highly curable malignancy, cancer survivors' lives and
lifestyles are altered substantially after receiving treatment for the
illness.
2
UI - 11712543
AU - D'Orazio AI
TI -
37th Annual American Society of Clinical Oncology Meeting. San
Francisco, CA. May 12-15, 2001.
SO - Clin Lymphoma 2001 Jun;2(1):11-7
3
UI - 11713166
AU - Konstantinov IE; Zehr KJ
TI -
Aortic root replacement in a patient with vancomycin-resistant
Enterococcus faecium endocarditis and leukemia.
SO - Chest 2001 Nov;120(5):1744-6
AD - Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN 55902,
USA.
Vancomycin-resistant Enterococcus faecium endocarditis is rare and
usually occurs in immunocompromised patients. We describe a patient with
hairy-cell leukemia and vancomycin-resistant E faecium endocarditis. The
patient presented with severe aortic insufficiency. He underwent aortic
root replacement with a cryopreserved aortic homograft and was treated
with a combination of quinupristin/dalfopristin, ampicillin, and
gentamicin.
4
UI - 11737252
AU - Colovic MD; Jankovic GM; Wiernik PH
TI -
Hairy cell leukemia in first cousins and review of the literature.
SO - Eur J Haematol 2001 Sep;67(3):185-8
AD - Institute of Hematology, University Clinical Center, Belgrade, Serbia,
Yugoslavia. marcolov@EUnet.yu
Familial hairy cell leukemia (HCL) occurs rarely. So far, 26 familial
instances of HCL (in 12 families) have been reported in the literature.
The consistent human leukocyte antigen (HLA) linkage could not be
established in most cases of familial HCL. History of exposure to
organic chemicals or employment in woodworking or farming was noted in
only two out of 11 affected families. We present two familial cases of
HCL as well as a thorough literature review. An influence of HLA or
farming themselves on a predisposition to HCL remains unproven but does
not rule out an HLA-linked and as yet unidentified gene responsible for
increased disease susceptibility. HCL in families is unlikely to be due
to random patterning, but there are insufficient data so far to
decisively incriminate either HLA-related or environmental causative
factors.
5
UI - 11736943
AU - Hagberg H; Lundholm L
TI -
Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment
of hairy cell leukaemia.
SO - Br J Haematol 2001 Dec;115(3):609-11
AD - Department of Oncology, Akademiska sjukhuset, Uppsala, Sweden.
hagberg@uppsala.mail.telia.com
The introduction of first alpha-interferon and later the purine
analogues has revolutionized the treatment of hairy cell leukaemia
(HCL). However, there are still some patients that initially or
eventually fail to respond and, thus, there is a need for alternative
treatment modalities. We have treated 11 HCL patients (eight relapsing
and three newly diagnosed) with a chimaeric monoclonal antibody,
rituximab, in a dose of 375 mg/m2 once a week for 4 weeks. The response
rate was seven out of eleven (64%) with six complete remissions and one
partial remission, all which have lasted between 0 and 34 months (median
14 months). Rituximab appears promising in the treatment of HCL and
warrants further studies.
6
UI - 11699427
AU - Undar B; Demirkan F; Oztop I; Ozcan MA; Ozsan GH
TI -
Concurrent diagnosis of hairy cell leukemia and renal cell carcinoma.
SO - Leuk Lymphoma 2001 Jul;42(3):567-8
7
UI - 11794207
AU - Saven A
TI -
Treatment of hairy-cell leukemia.
SO - N Engl J Med 2001 Nov 15;345(20):1500-1
8
UI - 3485222
AU - Brito-Babapulle V; Pittman S; Melo JV; Parreira L; Catovsky D
TI -
The 14q+ marker in hairy cell leukaemia. A cytogenetic study of 15
cases.
SO - Leuk Res 1986;10(2):131-8
Leukaemic cells from 19 patients with hairy cell leukaemia (HCL),
characterised by morphological, immunological and ultrastructural
criteria, were investigated for chromosome abnormalities after
stimulation with B-cell mitogens (Pokeweed mitogen (PWM),
lipopolysaccharide B and EBV). The cells from all cases had a B-cell
phenotype and in each case only a single light chain type was expressed
on the membrane of the cells. Only 15 patients with adequate metaphases
are included in this study. Clonal chromosome abnormalities were
observed in 12 patients of which five had a 14q + involving q32. Of the
remaining 3 cases 1 had nonclonal abnormalities and 2 had normal
karyotypes. The donor chromosomes were identified in 3 cases and were
found to be 9, 18 and 22. An interstitial rearrangement of chromosome 14
involving band q22 was seen in 2 cases and a deletion of chromosome 14
at q24 in 1 case. Amongst other chromosome abnormalities 12p was
involved in 4 cases, 12q in 2 cases and chromosomes 7 and 22 in 3 cases
each. The significance of the abnormalities has been discussed in
relation to sites of cellular oncogenes. Our study demonstrates that
chromosome abnormalities common to other B-cell disorders are present in
HCL.
9
UI - 3578132
AU - Diez Martin JL; Li CY; Banks PM
TI -
Blastic variant of hairy-cell leukemia.
SO - Am J Clin Pathol 1987 May;87(5):576-83
Three patients with hairy-cell leukemia presented with an unusual
combination of clinical and cytologic features. Clinical manifestations
included constitutional symptoms, progressive left upper abdomen
discomfort, and lymphadenopathy. All three had pancytopenia. Bone marrow
aspirate was hypercellular, with extensive replacement by abnormal
blastic mononuclear cells with a high nuclear/cytoplasmic ratio. Round,
oval, or indented nuclei, with reticular chromatin and prominent
nucleoli, and basophilic cytoplasm, with abundant large azurophilic
granules, were noted. The bone marrow biopsy specimen showed diffuse
involvement in two patients and patchy involvement in one, with absence
of fibrosis. The abnormal cells were intensely positive by
tartrate-resistant acid phosphatase stain. All of the patients responded
well initially to splenectomy. One, who presented with multiple
chromosomal abnormalities, had a relatively short survival. The other
two are alive. One started therapy with chlorambucil 21 months after
operation, and the other presented in a hyperleukocytotic phase five
years after operation and responded dramatically to 2'-deoxycoformycin.
10
UI - 6883301
AU - Sadamori N; Han T; Kakati S; Sandberg AA
TI -
Chromosomes and causation of human cancer and leukemia. LI. A hairy cell
leukemia case with 14q+ and ring chromosomes: significance of ring
chromosomes in blood disorders.
SO - Cancer Genet Cytogenet 1983 Sep;10(1):67-77
What appears to be the first hairy cell leukemia case with a 14q+
anomaly is described. In addition to the 14q+ anomaly, a 6q- and a ring
chromosome were seen in a blood sample stimulated with
lipopolysaccharide, a B-cell mitogen. The clinical course of the present
case was short, stormy, and had a poor response to therapy. The
correlation between the clinical course and the presence of a ring
chromosome in myelo- and lymphoproliferative blood disorders is
discussed in relation to the various blood disorders with this karyotype
anomaly described in the literature.
11
UI - 6677564
AU - Ueshima Y; Alimena G; Rowley JD; Golomb HM
TI -
Cytogenetic studies in patients with hairy cell leukemia.
SO - Hematol Oncol 1983 Jul-Sep;1(3):215-26
We performed cytogenetic studies on 58 patients with hairy cell leukemia
(HCL) from 1975 to 1981. Analysable metaphase cells stained with
Q-banding were obtained in 77 samples from 44 patients. Cells with
abnormal chromosomes were found in both unstimulated and stimulated
cultures of bone marrow and peripheral blood. Patients were classified
in 6 groups. Group I, 2 patients with a clonal chromosome abnormality;
group II, 13 patients with nonclonal structural abnormalities; group
III, 5 patients with nonclonal numerical abnormalities; group IV, 19
patients with only a normal karyotype; group V, 15 patients with no or
with fewer than 5 normal metaphase cells; group VI, 4 patients with
questionable abnormal chromosomes. Common abnormalities were deletion of
the long arm of No. 6 or +3 each in 3 patients, and +Y, +12 or +18 in 2
patients. Actuarial survival for each group was calculated from
diagnosis and also from chromosome examination. The two patients with a
clonal chromosome abnormality died within one year. Eight of 13 patients
with nonclonal structural abnormalities died within 5 years after
diagnosis, while none of 5 patients with nonclonal numerical
abnormalities and 2 of 19 patients with normal chromosomes died within 5
years. The difference in the 5-year actuarial survival between patients
with nonclonal abnormalities (groups II and III) and those with a normal
karyotype was significant (p less than 0.05). The difference was more
marked between patients with nonclonal structural abnormalities and
those with a normal karyotype (p less than 0.01). Patients with
nonclonal numerical abnormalities had a longer survival than those
patients with nonclonal structural abnormalities (p less than 0.05).
Thus, structural chromosome abnormalities in HCL may be a poor
prognostic sign even when they are not clonal.
12
UI - 7719244
AU - Foon KA
TI -
Chronic lymphoid leukemias: recent advances in biology and therapy.
SO - Stem Cells 1995 Jan;13(1):1-21
AD - Lucille Parker Markey Cancer Center, Department of Internal Medicine,
University of Kentucky Medical Center, Lexington 40536-0093, USA.
There exists a wide variety of lymphoid leukemias derived from B and T
lymphocytes. These diseases have distinct immunologic and biologic
features as well as varied responses to therapeutics. The most common
lymphoid leukemia is chronic lymphocytic leukemia (CLL) which is a
clonal proliferation of a subset of B cells expressing the CD5 antigen.
Prolymphocytic leukemia is usually derived from B cells and shares some
features with CLL but is clearly a distinct entity. Hairy-cell leukemia
is a B cell malignancy that is uniquely responsive to a variety of
biologic and chemotherapeutic agents. Waldenstrom's macroglobulinemia is
a B cell malignancy that secretes immunoglobulin M (IgM) and may present
with the hyperviscosity syndrome. Other B cell malignancies that less
commonly present as leukemias include non-Hodgkin's lymphomas such as
follicular lymphoma or mantle zone lymphoma. Multiple myeloma may rarely
present or evolve into a plasma cell leukemia, typically in far advanced
disease. T cell malignancies that may present as chronic lymphoid
leukemias, and in the past have often been referred to as T cell chronic
lymphocytic leukemia, are large granular lymphocytic leukemia, adult T
cell leukemia/lymphoma, Sezary cell leukemia and rare cases of
non-Hodgkin's lymphoma that are T cell derived and may present or evolve
into a leukemic phase. There is also a rare T cell counterpart of
prolymphocytic leukemia. Distinguishing these diseases is critical for
optimal care of these patients.
13
UI - 11566344
AU - Sambani C; Trafalis DT; Mitsoulis-Mentzikoff C; Poulakidas E;
TI -
Makropoulos V; Pantelias GE; Mecucci C
Clonal chromosome rearrangements in hairy cell leukemia: personal
experience and review of literature.
SO - Cancer Genet Cytogenet 2001 Sep;129(2):138-44
AD - Laboratory of Health Physics & Environmental Hygiene, I/NT-RP, NCSR
"Demokritos," 153 10 Aghia Paraskevi, Athens, Greece.
csambani@mail.demokritos.gr
Cytogenetic studies in hairy cell leukemia (HCL) are rare. In the
present report, cytogenetic investigations were performed on marrow
cells obtained from 21 HCL male patients with a mean age of 57 years and
active disease. Karyotypic analysis was successful in 18 of the 21
patients, either at diagnosis or in relapse after treatment with IFNa.
Clonal chromosome abnormalities were detected in eight of 18 cases. The
chromosome most frequently involved in the rearranged karyotypes was
chromosome 14. Results are discussed with respect to 79 abnormal HCL
cases obtained from an extensive review of the literature from 1978 to
2000.
14
UI - 11780695
AU - Heyman MR; Brown LA
TI -
A 66-year-old man with hepatosplenomegaly and pancytopenia.
SO - Am J Med Sci 2001 Dec;322(6):365-8
AD - Department of Medicine, University of Maryland School of Medicine,
Baltimore, USA.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
